Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

RARE PHOTOS: Cipla | Vintage Vibes

Airtel to Trent: 44 cos likely to report double-digit profit slump in Q1. Are your stocks on the list?

Motilal Oswal expects 44 companies, including Bharti Airtel, Trent, IndiGo, HAL, GAIL and Cipla, to report double-digit year-on-year profit declines in the June quarter. Higher energy costs, weaker demand, geopolitical tensions and margin pressure are expected to weigh on earnings, even as overall corporate profit growth slows in Q1.

The Economic Times

Cipla shares jump 4% as Citi puts stock on 90-day catalyst watch. What's driving the optimism?

Cipla's stock surged following Citi's 'Buy' rating and a 90-day Positive Catalyst Watch. The brokerage anticipates growth from potential US approvals like gFlovent and gVentolin, alongside a rebound in its US business. Domestically, Cipla's performance remains strong, supported by its respiratory portfolio. Citi sees earnings bottoming out and highlights attractive…

The Economic Times

Cipla appoints health chief Shivam Puri to lead One India business

Cipla has appointed Shivam Puri as the new Chief Executive Officer for its One India Business. This significant leadership change will take effect from July 1. Puri currently heads Cipla Health, a role he has held since 2019. His extensive experience in consumer goods and healthcare will now steer Cipla's…

The Economic Times

From analysis to the latest developments in health,
read the most diverse news in one place.

Adherex Technologies’ PEDMARK Push Targets Larger AYA Market After Record Quarter

Fennec Pharmaceuticals (NASDAQ:FENC) executives outlined the company’s commercial strategy for PEDMARK, its sodium thiosulfate product used to prevent cisplatin-related hearing loss, during a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference. Ram Selvaraju, managing dir

MarketBeat

Cipla shares rally 8% despite 55% YoY slump in Q4 profit. Why Citi, Nuvama, other brokerages hiked target

Cipla shares surged on Thursday, extending gains to nearly 11% in two sessions, after several brokerages turned bullish on the stock despite a weak Q4 performance. The stock hit an intraday high of Rs 1,432.10 as investors focused on future growth prospects over near-term earnings pressure.

The Economic Times

Cipla Q4 Results: Profit falls 55% YoY to Rs 555 crore; co declares Rs 13/sh dividend

Cipla Ltd announced a significant 55% year-on-year drop in its consolidated net profit for the fourth quarter, reaching Rs 555 crore. This contrasts with Rs 1,222 crore reported in the same period last year. The company's Board has recommended a final dividend of Rs 13 per share for the fiscal…

The Economic Times

Stocks in news: Airtel, Tata Motors, Dr Reddy's, NTPC, Dixon Technologies

Markets faced selling pressure on Tuesday due to weak global cues and macroeconomic concerns, with the Nifty approaching support at 23,150. Several companies like Airtel, Tata Motors, and Dr Reddy's are in focus due to earnings reports and other news developments.

The Economic Times

Read news from The Economist, FT, and more,
with one subscription

7 Things That Will Get Cheaper After Budget 2026

Most budgets promise relief. Very few actually change what you pay in real life. Budget 2026 is one of those rare ones that works quietly. There were no dramatic tax cuts, no loud announcements, and no instant price drops flashed across screens. Yet, beneath the fine print, the government made…

Times Life

3 High-Growth Biotech Stocks to Watch

Amid the growing innovations, emphasis on enhanced treatment alternatives, and rapid AI adoption, the biotechnology industry is poised for solid long-term growth. Thus, investors could consider adding high-growth biotech stocks MannKind (MNKD), Amicus Therapeutics (FOLD), and Esperion Therapeutics (ESPR) to their watchlist. Continue reading.

StockNews.com

3 Biotech Stocks to Buy Before Their Earnings Announcements

Buoyed by encouraging clinical trial results and new advancements, the biotech industry is on a strong upward trajectory. Given the sector’s growing potential, I have highlighted three biotech stocks, Exelixis (EXEL), Gilead Sciences (GILD), and Halozyme Therapeutics (HALO), to consider before their second-quarter earnings report. Read on….

StockNews.com

‘My posts are backed up with solid evidence, research’: Liver Doc on Himalaya Wellness suit

“Based on strong scientific evidence, or because of lack of it, I have been critical of several of Himalaya Wellness’ products,” said doctor-influencer Cyriac Abby Philips aka The Liver Doc, whose X account was suspended today for posting “defamatory remarks” against the ayurvedic pharma company.

Newslaundry

Revealed: Hundreds of millions in UK taxpayers’ money handed to companies still operating in Russia

Exclusive: British government accused of indirectly helping to fund Putin’s war with £294m contracts

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.